NCT00430235View on ClinicalTrials.gov

A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2010

Conditions
Adenocarcinoma of the Prostate
Interventions
DRUG

BAY 43-9006

BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)

Trial Locations (1)

V5Z 4E6

BC Cancer Agency - Vancouver Centre, Vancouver

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER

NCT00430235 - A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter